Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$29.40 USD
+0.53 (1.84%)
Updated May 31, 2024 04:00 PM ET
After-Market: $29.44 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.40 USD
+0.53 (1.84%)
Updated May 31, 2024 04:00 PM ET
After-Market: $29.44 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Zacks News
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 87.04% and 0.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Strength Seen in Harmony Biosciences Holdings, Inc. (HRMY): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Harmony Biosciences (HRMY) Stock Might be a Great Pick
by Zacks Equity Research
Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Harmony Biosciences Holdings, Inc. (HRMY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?
by Zacks Equity Research
Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 42.50% and 7.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q1 Earnings Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 96.88% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Berkeley Lights, Inc. (BLI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -4% and 5.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 88.89% and 1.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences Holdings, Inc. (HRMY) Surges 10.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks.com featured highlights include: Alpha and Omega Semiconductor, Preferred Apartment Communities, Hut 8 Mining, GCM Grosvenor and Harmony Biosciences
by Zacks Equity Research
Zacks.com featured highlights include: Alpha and Omega Semiconductor, Preferred Apartment Communities, Hut 8 Mining, GCM Grosvenor and Harmony Biosciences
5 Stocks for Higher Returns as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like Alpha and Omega (AOSL), Preferred Apartment (APTS), Hut 8 Mining (HUT), GCM (GCMG) & Harmony Biosciences (HRMY).
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12
by Zacks Equity Research
Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.
Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance
by Zacks Equity Research
Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
by Zacks Equity Research
The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.
Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More
by Kinjel Shah
Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.